Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Feb 12, 2026 · 10-Q · 43 days after period end · 0001140361-26-004924
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$2.32M | -$4.16M | -$2.39M | -$3.89M |
| EPS Diluted | -$0.14 | -$0.36 | -$0.21 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Feb 12, 2026 · 43 d after period end
